Meiqi Wu
Beijing, 100730, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Integrated 18F-NOTA-FAPI-04 PET/MRI for quantitative assessment of disease activity in thyroid-associated ophthalmopathy.
Journal: European journal of nuclear medicine and molecular imaging
Published: May 08, 2026
Standardized quantification of [18F]Florbetazine amyloid PET with the Centiloid scale.
Journal: NeuroImage
Published: October 12, 2025
Real world clinical practice of lecanemab at PUMCH dementia cohort: focus on dynamic imaging and biomarker evolution.
Journal: Alzheimer's research & therapy
Published: September 22, 2025
Comparison of diagnostic accuracy of Alzheimer's disease cerebrospinal fluid core biomarkers using INNOTEST, Lumipulse G, and Elecsys assays: Insights from the PUMCH dementia cohort study.
Journal: Journal of Alzheimer's disease : JAD
Published: September 17, 2025
Predictive Accuracy of a Clinical Model for Carriage of Pathogenic/Likely Pathogenic Variants in Patients with Dementia and a Positive Family History at PUMCH.
Journal: Biomedicines
Published: March 30, 2025
The diagnostic performance of [18F]Florbetazine in Alzheimer's disease: a head-to-head comparison to [11C]PiB and [18F]Florbetapir.
Journal: European journal of nuclear medicine and molecular imaging
Published: January 22, 2025
Ultra-fast [18F]florbetapir PET imaging using the uMI Panorama PET/CT system.
Journal: EJNMMI physics
Published: August 04, 2024
Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: March 13, 2023
Generalized Muscular Hypermetabolism Caused by Mitochondrial Myopathy Shown on 18 F-FDG PET/CT.
Journal: Clinical nuclear medicine
Published: January 11, 2023
Metabolic Tumor Volume Measured by 18F-FDG PET/CT is Associated with the Survival of Unresectable Hepatocellular Carcinoma Treated with PD-1/PD-L1 Inhibitors Plus Molecular Targeted Agents.
Journal: Journal of hepatocellular carcinoma
Published: December 28, 2022
Last Updated: 09/26/2026